Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation
- 12 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (1) , 38-50
Abstract
Atrial fibrillation (AF) produces a hypercoagulable state. Stimulation of protease-activated receptors by coagulation factors provokes pro-fibrotic, pro-hypertrophic, and pro-inflammatory responses in a variety of tissues. We studied the effects of thrombin on atrial fibroblasts and tested the hypothesis that hypercoagulability contributes to the development of a substrate for AF. In isolated rat atrial fibroblasts, thrombin enhanced the phosphorylation of the pro-fibrotic signalling molecules Akt and Erk and increased the expression of transforming growth factor β1 (2.7-fold) and the pro-inflammatory factor monocyte chemoattractant protein-1 (6.1-fold). Thrombin also increased the incorporation of 3H-proline, suggesting enhanced collagen synthesis by fibroblasts (2.5-fold). All effects could be attenuated by the thrombin inhibitor dabigatran. In transgenic mice with a pro-coagulant phenotype (TMpro/pro), the inducibility of AF episodes lasting >1 s was higher (7 out of 12 vs. 1 out of 10 in wild type) and duration of AF episodes was longer compared with wild type mice (maximum episode duration 42.8 ± 68.4 vs. 0.23 ± 0.39 s). In six goats with persistent AF treated with nadroparin, targeting Factor Xa-mediated thrombin generation, the complexity of the AF substrate was less pronounced than in control animals (LA maximal activation time differences 23.3 ± 3.1 ms in control vs. 15.7 ± 2.1 ms in nadroparin, P < 0.05). In the treated animals, AF-induced α-smooth muscle actin expression was lower and endomysial fibrosis was less pronounced. The hypercoagulable state during AF causes pro-fibrotic and pro-inflammatory responses in adult atrial fibroblasts. Hypercoagulability promotes the development of a substrate for AF in transgenic mice and in goats with persistent AF. In AF goats, nadroparin attenuates atrial fibrosis and the complexity of the AF substrate. Inhibition of coagulation may not only prevent strokes but also inhibit the development of a substrate for AF.Keywords
Funding Information
- Netherlands Heart Foundation
- European Union (261057, 633196)
- Interuniversity Cardiology Institute Netherlands
- Netherlands Organisation of Scientific research
- NWO (016.136.055)
This publication has 40 references indexed in Scilit:
- Protease-Activated Receptor 1 Inhibition by SCH79797 Attenuates Left Ventricular Remodeling and Profibrotic Activities of Cardiac FibroblastsJournal of Cardiovascular Pharmacology and Therapeutics, 2013
- Genetic and Pharmacological Modifications of Thrombin Formation in Apolipoprotein E-deficient Mice Determine Atherosclerosis Severity and Atherothrombosis Onset in a Neutrophil-Dependent MannerPLOS ONE, 2013
- Protease‐activated receptors and myocardial infarctionIUBMB Life, 2011
- Protease-Activated Receptor 2 Deficiency Reduces Cardiac Ischemia/Reperfusion InjuryArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Factor X/Xa Elicits Protective Signaling Responses in Endothelial Cells Directly via PAR-2 and Indirectly via Endothelial Protein C Receptor-dependent Recruitment of PAR-1Journal of Biological Chemistry, 2010
- Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overloadJournal of Clinical Investigation, 2010
- Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblastsArthritis & Rheumatism, 2009
- Is thrombin a key player in the 'coagulation-atherogenesis' maze?Cardiovascular Research, 2009
- Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and HypertrophyCirculation, 2007
- Protease-Activated Receptor-1–Mediated DNA Synthesis in Cardiac Fibroblast Is via Epidermal Growth Factor Receptor TransactivationCirculation Research, 2002